US FDA tightens regulatory noose on Indian drug firms

Indian drug makers have again come under the scrutiny of the US Food and Drug Administration (US FDA), making the pharmaceutical industry and investors sit up. Ranbaxy, the Paonta Sahib and Dewas units of which are already barred from supplying medicines to the US and are undergoing a consent decree with the regulator there, has got another import alert — for its Mohali facility this time.

Read Full Story>>